KeyBanc analyst Brett Fishbin maintains $ICU Medical (ICUI.US)$ with a buy rating, and adjusts the target price from $147 to $198.
According to TipRanks data, the analyst has a success rate of 94.1% and a total average return of 22.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $ICU Medical (ICUI.US)$'s main analysts recently are as follows:
The firm is encouraged by considerable advancements made thus far in the year, showcasing enhanced operational stability. With guidance remaining on the conservative side, there is a belief in the potential for sustained outperformance moving into the latter half of 2024. Additionally, there are several factors that could drive further upside in 2025.
ICU Medical is recognized for its robust usage environment and a commanding presence in the expanding market for IVs and disposables. Despite these strengths, analysis and industry feedback indicate that the company is not expected to capture significant market share from its main competitors, which results in projections that align with the general consensus.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
KeyBanc分析師Brett Fishbin維持$ICU醫療 (ICUI.US)$買入評級，並將目標價從147美元上調至198美元。
根據TipRanks數據顯示，該分析師近一年總勝率為94.1%，總平均回報率為22.3%。
此外，綜合報道，$ICU醫療 (ICUI.US)$近期主要分析師觀點如下：
該公司對今年迄今爲止取得的重大進展感到鼓舞，這表明運營穩定性得到增強。由於指導方針仍然偏向保守，人們相信到2024年下半年，業績有可能持續跑贏大盤。此外，有幾個因素可能會推動2025年進一步上漲。
ICU Medical因其強大的使用環境以及在不斷擴大的IV和一次性用品市場中佔據主導地位而獲得認可。儘管有這些優勢，但分析和行業反饋表明，預計該公司不會從主要競爭對手手中奪取大量市場份額，這導致預測與普遍共識一致。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
